← The Wire
TBPHNasdaq
Theravance Biopharma, Inc.
Pharmaceutical Preparations · CA · CIK 1583107
Theravance Biopharma develops and commercializes medicines, earning revenue from collaborations and licensing
red 8-K · 90d⚡ Elevated coverage
$858M
Market cap
$17.06
Last close
-3.2%
1D
+3.0%
5D
3.1M
Volume
Price · last 39 sessions+0.9%
May 4L $15.58 · H $17.63Jun 29
261
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
SC 13GSC 13GAug 16, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GJun 16, 2022SC 13GSC 13GApr 21, 2022SC 13GSC 13GSep 27, 2021SC 13GSCHEDULE 13GSep 7, 2021SC 13GSCHEDULE 13GFeb 12, 2021SC 13GSEC SCHEDULE 13GJan 28, 2020SC 13GSC 13GOct 29, 2019SC 13GSC 13GFeb 10, 2017SC 13GSC 13GNov 10, 2016SC 13GSCHEDULE 13GNov 10, 2015SC 13GSCHEDULE 13GNov 10, 2015SC 13GSC 13GSep 2, 2015
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $434K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $14.00 | $217K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $13.92 | $108K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $13.92 | $108K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $18.75 | $291K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $18.75 | $146K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $18.75 | $146K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 15,501 | $20.00 | $310K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 14,000 | $20.00 | $280K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 29,500 | $18.50 | $546K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $18.50 | $287K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 2 reputable articles · skews ▲ positive.
ReutersZymeworks expands beyond cancer with $929 million Theravance acquisition22h agoBarron'sZymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.23h ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance